
## Swapnil S Potdar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3726100/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia. Cancer Discovery, 2022, 12, 388-401.	9.4	73
2	Targeting Apoptosis Pathways With BCL2 and MDM2 Inhibitors in Adult B-cell Acute Lymphoblastic Leukemia. HemaSphere, 2022, 6, e701.	2.7	4
3	High miR-30 Expression Associates with Improved Breast Cancer Patient Survival and Treatment Outcome. Cancers, 2021, 13, 2907.	3.7	3
4	Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia. Npj Precision Oncology, 2021, 5, 71.	5.4	12
5	High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma. Scientific Reports, 2021, 11, 14755.	3.3	7
6	Functional diagnostics using fresh uncultured lung tumor cells to guide personalized treatments. Cell Reports Medicine, 2021, 2, 100373.	6.5	6
7	ALDH1A1â€related stemness in highâ€grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTORâ€PI3K/aurora kinase inhibitors. Journal of Pathology, 2020, 250, 159-169.	4.5	37
8	Human Tumor–Derived Matrix Improves the Predictability of Head and Neck Cancer Drug Testing. Cancers, 2020, 12, 92.	3.7	20
9	KIT pathway upregulation predicts dasatinib efficacy in acute myeloid leukemia. Leukemia, 2020, 34, 2780-2784.	7.2	6
10	Characterization of p190-Bcr-Abl chronic myeloid leukemia reveals specific signaling pathways and therapeutic targets. Leukemia, 2020, 35, 1964-1975.	7.2	35
11	Breeze: an integrated quality control and data analysis application for high-throughput drug screening. Bioinformatics, 2020, 36, 3602-3604.	4.1	68
12	Intertumoral heterogeneity in patient-specific drug sensitivities in treatment-naÃ <sup>-</sup> ve glioblastoma. BMC Cancer, 2019, 19, 628.	2.6	55
13	Receptor Tyrosine Kinase Signaling Networks Define Sensitivity to ERBB Inhibition and Stratify <i>Kras</i> -Mutant Lung Cancers. Molecular Cancer Therapeutics, 2019, 18, 1863-1874.	4.1	8
14	Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas. British Journal of Cancer, 2019, 120, 435-443.	6.4	24
15	Feasibility study of using highâ€ŧhroughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment. Clinical and Translational Medicine, 2019, 8, 33.	4.0	20
16	Prediction of drug combination effects with a minimal set of experiments. Nature Machine Intelligence, 2019, 1, 568-577.	16.0	99
17	Comparative Analysis of Independent Ex Vivo functional Drug Screens Identifies Predictive Biomarkers of BCL-2 Inhibitor Response in AML. Blood, 2018, 132, 2763-2763.	1.4	1
18	Targeting BCL-2, BCL-XL, BCL-W and MDM2 in B-Cell Acute Lymphoblastic Leukemia Is Highly Effective Ex Vivo, Blood, 2018, 132, 3975-3975.	1.4	0

#	Article	IF	CITATIONS
19	Identification and Clinical Exploration of Individualized Targeted Therapeutic Approaches in Acute Myeloid Leukemia Patients By Integrating Drug Response and Deep Molecular Profiles. Blood, 2017, 130, 854-854.	1.4	1
20	Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors. Oncotarget, 2017, 8, 22606-22615.	1.8	13
21	A personalised medicine drug sensitivity and resistance testing platform and utilisation of acoustic droplet ejection at the Institute for Molecular Medicine Finland. Synergy, 2014, 1, 78.	1.1	4
22	A Profound Biological Difference of Chronic and Blast Phase Chronic Myeloid Leukemia in Ex Vivo Drug Responses. Blood, 2014, 124, 3139-3139.	1.4	0